Answers are grounded in this paper and cite their sources.
Bone and brain metastases are rare in colorectal cancer, and prior studies have treated metastasis as a fixed baseline characteristic. We conducted a multicenter retrospective study of patients with colorectal cancer and bone and/or brain metastases at Turkish Oncology Group centers (May 2011 to September 2025). In multivariable Cox models, the opposite rare-site metastasis and post-metastasis targeted therapy were modeled as time-dependent covariates. Among 188 patients, 139 (73.9%) had bone-first, 33 (17.6%) brain-first, and 16 (8.5%) synchronous disease. Median overall survival was 13.6 months (95% CI 11.6 to 16.4), with no difference by phenotype (p = 0.705). Opposite-site involvement was associated with higher mortality in the bone-metastasis (aHR 2.149, p = 0.006) and brain-metastasis (aHR 2.076, p = 0.018) cohorts, reflecting brain metastasis developing during follow-up in the former and bone metastasis present at diagnosis in the latter. Carcinoembryonic antigen and neutrophil-to-lymphocyte ratio were independently prognostic (both p < 0.01). Anti-EGFR (aHR 0.356, p = 0.001) and anti-VEGF therapy (aHR 0.471, p = 0.005) were associated with lower mortality in patients with bone metastasis but not in those with brain metastasis. Brain metastasis developing in patients with bone metastases carries independent prognostic weight, while targeted-therapy associations in brain metastasis remain inconclusive.
No takes yet. Share an insight, caveat, or question.
Başkurt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: